FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311558013> ?p ?o ?g. }

• W4311558013 abstract "Abstract Background Strategies to combat COVID include vaccines and Monoclonal Antibody Therapy (MAB). While vaccines aim to prevent symptom development, MAB aims to prevent progression of mild symptoms to severe. Increasing numbers of COVID infections in vaccinated patients raised the question of whether vaccinated and unvaccinated patients respond differently to MAB. Methods We performed a retrospective review of the medical charts to evaluate responses of MAB in vaccinated and unvaccinated COVID patients by measuring the number of emergency department (ED) visits, hospitalizations, and ICU admissions within 14 days and the 30-day mortality following MAB. We evaluated outcomes according to vaccination status using absolute risk reduction and used Chi-squared tests to assess statistical significance using an alpha of p&lt; 0.05. We used multivariable generalized linear models with a log link and binomial distribution to estimate adjusted relative risk and 95% confidence intervals. Figure 1:Subject Flow Diagram Results Based on the inclusion criteria, we found 4,128 patients from which 230 had missing vaccination information or dose. From 3898 included patients, 296 (7.59%) visited the ED, 154 (3.95%) were hospitalized, and 25 (0.64%) were in ICU within 14 days of infusion. 12 patients (0.31%) died within 30 days. 2009 (51.5%) were unvaccinated at the time of infusion. Demographics were similar in both groups except that most of the patients in both groups were Non-Hispanic Caucasians, raising the question of racial and ethnic disparities. All comorbidities except pregnancy were predominant in the vaccinated group. Unvaccinated patients were more likely to receive MAB after 7 days of symptoms and in the ER, suggesting that they may have had more severe disease at the time of infusion, despite having less comorbidities. Unvaccinated patients had more ED visits (11.2% vs 4.3%, p&lt; 0.0001), hospitalizations (6.2% vs 2.1%, p&lt; 0.0001), and deaths (1.1% vs 0.3%, p=0.005) following infusion. Adjusted for demographics and comorbidities, unvaccinated patients were 2.41 times more likely to seek help in the ED and 2.73 times to be hospitalized. Figure 2:Patient Demographics and ComorbiditiesFigure 3:Comparison of Outcomes by Vaccination StatusFigure 4:Relative Risk by Vaccination Status Model 1 – Unadjusted Model 2 – Adjusted for financial class, infusion location, patient sex, patient age, patient race, and time to infusion Model 3 – Model 2 Variables + Comorbidity Count Model 4 – Model 2 + Specific Comorbidities (diabetes, cancer, immunosuppression, BMI, chronic kidney disease, cardiovascular disease, lung disease, neurological disorders, and smoking) Conclusion Our data confirms that immunization plays a key role in reducing COVID-related morbidity and mortality. It also supports MAB efficiency from clinical trials. Figure 5:Future Actions Disclosures All Authors: No reported disclosures." @default.
• W4311558013 created "2022-12-27" @default.
• W4311558013 creator A5013798314 @default.
• W4311558013 creator A5021723284 @default.
• W4311558013 creator A5033434338 @default.
• W4311558013 creator A5072281274 @default.
• W4311558013 creator A5076258650 @default.
• W4311558013 date "2022-12-01" @default.
• W4311558013 modified "2023-09-26" @default.
• W4311558013 title "1151. Retrospective Analysis of Vaccinated and Unvaccinated Monoclonal Antibody Patients and their Emergent Needs (RAVEN) and Hospital Utilization" @default.
• W4311558013 doi "https://doi.org/10.1093/ofid/ofac492.989" @default.
• W4311558013 hasPublicationYear "2022" @default.
• W4311558013 type Work @default.
• W4311558013 citedByCount "0" @default.
• W4311558013 crossrefType "journal-article" @default.
• W4311558013 hasAuthorship W4311558013A5013798314 @default.
• W4311558013 hasAuthorship W4311558013A5021723284 @default.
• W4311558013 hasAuthorship W4311558013A5033434338 @default.
• W4311558013 hasAuthorship W4311558013A5072281274 @default.
• W4311558013 hasAuthorship W4311558013A5076258650 @default.
• W4311558013 hasBestOaLocation W43115580131 @default.
• W4311558013 hasConcept C126322002 @default.
• W4311558013 hasConcept C167135981 @default.
• W4311558013 hasConcept C187212893 @default.
• W4311558013 hasConcept C194828623 @default.
• W4311558013 hasConcept C203014093 @default.
• W4311558013 hasConcept C22070199 @default.
• W4311558013 hasConcept C44249647 @default.
• W4311558013 hasConcept C65409693 @default.
• W4311558013 hasConcept C71924100 @default.
• W4311558013 hasConceptScore W4311558013C126322002 @default.
• W4311558013 hasConceptScore W4311558013C167135981 @default.
• W4311558013 hasConceptScore W4311558013C187212893 @default.
• W4311558013 hasConceptScore W4311558013C194828623 @default.
• W4311558013 hasConceptScore W4311558013C203014093 @default.
• W4311558013 hasConceptScore W4311558013C22070199 @default.
• W4311558013 hasConceptScore W4311558013C44249647 @default.
• W4311558013 hasConceptScore W4311558013C65409693 @default.
• W4311558013 hasConceptScore W4311558013C71924100 @default.
• W4311558013 hasIssue "Supplement_2" @default.
• W4311558013 hasLocation W43115580131 @default.
• W4311558013 hasOpenAccess W4311558013 @default.
• W4311558013 hasPrimaryLocation W43115580131 @default.
• W4311558013 hasRelatedWork W1966393931 @default.
• W4311558013 hasRelatedWork W2105151527 @default.
• W4311558013 hasRelatedWork W2331820588 @default.
• W4311558013 hasRelatedWork W2810456594 @default.
• W4311558013 hasRelatedWork W2951130915 @default.
• W4311558013 hasRelatedWork W3009852707 @default.
• W4311558013 hasRelatedWork W3095141535 @default.
• W4311558013 hasRelatedWork W3208090289 @default.
• W4311558013 hasRelatedWork W3210359220 @default.
• W4311558013 hasRelatedWork W4255376461 @default.
• W4311558013 hasVolume "9" @default.
• W4311558013 isParatext "false" @default.
• W4311558013 isRetracted "false" @default.
• W4311558013 workType "article" @default.